We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
LPL Financial's April Brokerage and Advisory Assets Increase
Read MoreHide Full Article
LPL Financial Holdings Inc.’s (LPLA - Free Report) total brokerage and advisory assets of $699.3 billion at the end of April 2019 improved 7.2% year over year and 2.2% sequentially. Of the total brokerage and advisory assets, brokerage assets were $378.2 billion while advisory assets totaled $320.5 billion.
Further, total net new assets were an inflow of $0.7 billion in April. This included $0.3 billion of outflows from a large hybrid firm. Prior to these outflows, total net new assets were an inflow of $1 billion.
LPL Financial reported $29.2 billion of total client cash sweep balances, up 1% from April 2018 but down 4.9% from the prior month. Of the total, $20.7 billion was insured cash and $4.1 billion was deposit cash while the remaining $4.4 billion was money market cash balance.
With the decent equity markets performance, trading activities are anticipated to improve. This will likely result in an increase in brokerage and advisory assets, which in turn will support revenues.
Shares of LPL Financial have rallied 35.2% so far this year, outperforming 7.7% rise for the industry.
E*TRADE Financial reported monthly market activity for April 2019. Daily Average Revenue Trades (DARTs) for the month were 272,858, down 5% from the previous month but up 13% year over year. Derivatives comprised 32% of DARTs in April.
Interactive Brokers Group, Inc. (IBKR - Free Report) released its Electronic Brokerage segment’s performance metrics for April. The segment, which deals with the clearance and settlement of trades for individual and institutional clients globally, reported a year-over-year and sequential decrease in DARTs. Total client DARTs were 778,000, down 4% from April 2018 and 10% from March 2019.
Charles Schwab (SCHW - Free Report) reported monthly activity for April 2019. Total client assets came in at $3.7 trillion, up 11% from the year-ago month and 2% from the prior month. Further, client assets receiving ongoing advisory services were $1.913.7 trillion, up 11% year over year and 2% sequentially.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
LPL Financial's April Brokerage and Advisory Assets Increase
LPL Financial Holdings Inc.’s (LPLA - Free Report) total brokerage and advisory assets of $699.3 billion at the end of April 2019 improved 7.2% year over year and 2.2% sequentially. Of the total brokerage and advisory assets, brokerage assets were $378.2 billion while advisory assets totaled $320.5 billion.
Further, total net new assets were an inflow of $0.7 billion in April. This included $0.3 billion of outflows from a large hybrid firm. Prior to these outflows, total net new assets were an inflow of $1 billion.
LPL Financial reported $29.2 billion of total client cash sweep balances, up 1% from April 2018 but down 4.9% from the prior month. Of the total, $20.7 billion was insured cash and $4.1 billion was deposit cash while the remaining $4.4 billion was money market cash balance.
With the decent equity markets performance, trading activities are anticipated to improve. This will likely result in an increase in brokerage and advisory assets, which in turn will support revenues.
Shares of LPL Financial have rallied 35.2% so far this year, outperforming 7.7% rise for the industry.
LPL Financial currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Performance of Other Investment Brokers
E*TRADE Financial reported monthly market activity for April 2019. Daily Average Revenue Trades (DARTs) for the month were 272,858, down 5% from the previous month but up 13% year over year. Derivatives comprised 32% of DARTs in April.
Interactive Brokers Group, Inc. (IBKR - Free Report) released its Electronic Brokerage segment’s performance metrics for April. The segment, which deals with the clearance and settlement of trades for individual and institutional clients globally, reported a year-over-year and sequential decrease in DARTs. Total client DARTs were 778,000, down 4% from April 2018 and 10% from March 2019.
Charles Schwab (SCHW - Free Report) reported monthly activity for April 2019. Total client assets came in at $3.7 trillion, up 11% from the year-ago month and 2% from the prior month. Further, client assets receiving ongoing advisory services were $1.913.7 trillion, up 11% year over year and 2% sequentially.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>